HEALTHWDIV CLICKONDETROIT
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
The FDA is considering Moderna's first mRNA-based flu vaccine, mFlusiva, for adults 50 and older. A study showed it reduced flu cases by 27% compared to a standard vaccine, but lacks data on very frail older adults. The decision follows a dispute with a former FDA official who questioned the study's design.
Mentioned
Related Signal
Adjacent reporting
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
- Common vaccine slashes Alzheimer's disease risk when dose is increased
- Moderna mRNA flu vaccine to get FDA panel review
- FDA Staff Weighs In on Potential First mRNA Flu Shot
- AI-designed 'universal vaccine' passes first human clinical trial, could prevent future pandemics